advertisement
advertisement

Is it truly over for Theranos?

Theranos, the fallen unicorn, this week voided two years of test results according to a report in the Wall Street Journal. The company must still have some money in the bank—it raised more than $680 million in cash—but the Internet is damn near convinced that there’s no future for the blood-testing startup.  Theranos Voids 2 … Continue reading “Is it truly over for Theranos?”

Theranos, the fallen unicorn, this week voided two years of test results according to a report in the Wall Street Journal. The company must still have some money in the bank—it raised more than $680 million in cash—but the Internet is damn near convinced that there’s no future for the blood-testing startup. 

advertisement

advertisement
advertisement

About the author

Christina Farr is a San Francisco-based journalist specializing in health and technology. Before joining Fast Company, Christina worked as a reporter for VentureBeat, Reuters and KQED

More